Back Hepatitis B Hepatitis B Topics HBV Treatment

AASLD 2015: Hepatitis B Core Inhibitor NVR 3-778 Inhibits Viral Replication

Novira Therapeutics' NVR 3-778, a novel drug that interferes with the hepatitis B virus (HBV) core protein, blocked replication of various types of HBV in a laboratory study and reduced HBV viral load with no apparent safety issues in an early human trial, researchers reported at the AASLD Liver Meeting in November.

alt

Read more:

Chinese Herbs Taken with Lamivudine May Reduce Hepatitis B Mortality

Hepatitis B patients who used traditional Chinese medicine, including the herbal preparation Jia-Wei-Xiao-Yao-San, while being treated with lamivudine (3TC or Epivir) were less likely to die of any cause than non-users, according to research published in the November 4, 2015, Journal of Enthopharmacology.

alt

Read more:

Coverage of the 2015 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.

Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver  cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.

Full listing by topic

Liver Meeting website

11/23/15

alt

Tenofovir Alafenamide Is Effective Against Hepatitis B with Less Kidney and Bone Toxicity

A pair of Phase 3 studies have shown that Gilead Sciences' new tenofovir alafenamide (TAF) suppresses hepatitis B virus (HBV) as well as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on the kidneys and bones, the company announced this week.

alt

Read more:

AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection

The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load, and increased anti-HBs antibody titers, according to findings from a small Phase 2 study presented at the AASLD Liver Meeting taking place this week in San Francisco. Participants fell into 2 distinct groups, with half being partial responders and half full responders.

alt

Read more: